VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Atrium Therapeutics Executive Compensation (FY24)

RNA · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Sarah Boyce
Latest say-on-pay support
=
June 10, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Atrium Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 10, 2025
5 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Atrium Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
274 figures on this page: 270 cited to the filing that reported them, 4 calculated from figures it prints. See the citations

More on Atrium Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sarah Boyce: $11,139,719 → $14,176,480 (27.3% higher)
Say-on-pay support: 98.5% → 76.1% (22.4 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Atrium Therapeutics' chief executive and what were they paid?
Sarah Boyce, President and Chief Executive Officer, received $14,176,480 in total compensation for fiscal 2024. Boyce's total was 27.3% higher than the $11,139,719 reported for fiscal 2023.
What was Atrium Therapeutics' say-on-pay result?
The say-on-pay proposal drew 76.1% of votes cast for or against in favor at the meeting held June 10, 2025 for fiscal 2024.
Which companies are in Atrium Therapeutics' peer group?
Companies named in the disclosed peer group include Arcturus Therapeutics Holdings, Beam Therapeutics, Crinetics Pharmaceuticals, Dyne Therapeutics and Erasca, among others.
What is Atrium Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 48:1 for fiscal 2024, against median employee compensation of $297,345.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sarah Boyce
President and Chief Executive Officer
◇——◇◇—◇◇
Teresa McCarthy
Chief Human Resources Officer
◇——◇◇—◇◇
W. Michael Flanagan
Chief Scientific Officer
◇——◇◇—◇◇
Michael MacLean
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sarah Boyce
President and Chief Executive Officer
◇—◇◇◇—◇◇
W. Michael Flanagan
Chief Scientific Officer
◇—◇◇◇—◇◇
Michael MacLean
Chief Financial Officer
◇—◇◇◇—◇◇
Teresa McCarthy
Chief Human Resources Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Sarah Boyce
President and Chief Executive Officer
◇—◇◇◇—◇◇
John Moriarty
Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
Michael MacLean
Chief Financial Officer
◇—◇◇◇—◇◇
W. Michael Flanagan
Chief Scientific Officer
◇—◇◇◇—◇◇
Teresa McCarthy
Chief Human Resources Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
John B. Moriarty JrPSU◇——◇——◇
John B. Moriarty JrRSU◇——◇——◇
John B. Moriarty JrOPTION◇——◇—◇◇
Michael F. MacLeanOPTION◇——◇—◇◇
Michael F. MacLeanPSU◇——◇——◇
Michael F. MacLeanRSU◇——◇——◇
Sarah BoycePSU◇——◇——◇
Sarah BoyceRSU◇——◇——◇
Sarah BoyceOPTION◇——◇—◇◇
Teresa McCarthyPSU◇——◇——◇
Teresa McCarthyRSU◇——◇——◇
Teresa McCarthyOPTION◇——◇—◇◇
W. Michael FlanaganPSU◇——◇——◇
W. Michael FlanaganRSU◇——◇——◇
W. Michael FlanaganOPTION◇——◇—◇◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sarah BoyceRSU◇◇——
Option◇—◇1/20/2034
Option◇—◇1/20/2033
Option◇—◇9/11/2033
Option◇—◇1/21/2032
RSU◇◇——
RSU◇◇——
Option◇—◇2/2/2031
John MoriartyOption◇—◇8/1/2034
RSU◇◇——
RSU◇◇——
Michael MacLeanOption◇—◇1/20/2034
Option◇—◇1/20/2033
RSU◇◇——
Option◇—◇9/11/2033
Option◇—◇1/21/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/2/2031
W. Michael FlanaganOption◇—◇1/20/2033
RSU◇◇——
Option◇—◇1/20/2034
Option◇—◇9/11/2033
Option◇—◇1/21/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/21/2031
Teresa McCarthyRSU◇◇——
Option◇—◇1/20/2034
Option◇—◇1/20/2033
Option◇—◇1/21/2032
Option◇—◇9/11/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/2/2031
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
John Moriarty
General Counsel · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Michael MacLean
Chief Financial Officer · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Sarah Boyce
President and Chief Executive Officer · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Teresa McCarthy
Chief Human Resources Officer · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
W. Michael Flanagan
Chief Scientific Officer · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Simona Skerjanec
◇—◇———◇
Troy Wilson, Ph.D., J.D
◇—◇———◇
Noreen Henig, M.D
◇—◇———◇
Carsten Boess
◇—◇———◇
Edward M. Kaye, M.D
◇—◇———◇
Tamar Thompson
◇—◇———◇
Jean Kim
◇—◇———◇
Sarah Boyce and Arthur A. Levin, Ph.D served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Arcturus Therapeutics Holdings ARCT
  • Beam Therapeutics BEAM
  • Crinetics Pharmaceuticals CRNX
  • Dyne Therapeutics DYN
  • Erasca ERAS
  • IGM Biosciences IGMS
  • Inhibrx Inc INBX
  • Janux Therapeutics JANX
  • Kymera Therapeutics KYMR
  • Pliant Therapeutics PLRX
  • RAPT Therapeutics RAPT
  • Rocket Pharmaceuticals RCKT
  • Stoke Therapeutics STOK
  • Vaxcyte PCVX
  • Ventyx Biosciences VTYX
  • Verve Therapeutics VERV
  • Zentalis Pharmaceuticals ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 10, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sarah Boyce (President and Chief Executive Officer), FY2024 total compensation $14,176,480 (base salary $659,900) [exec_comp, SEC accession 0001599901-25-000092, filed 2025-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Atrium Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Atrium Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Atrium Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Atrium Therapeutics' disclosed peer group is defensible, who names Atrium Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
274 figures on this page: 270 cited to the filing that reported them, 4 calculated from figures it prints.
270 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001599901-25-000111
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001599901-25-000092
    CEO PAY RATIO · COMPENSATION TABLES · DIRECTOR COMPENSATION · Potential Payments Upon Termination
  3. 0001599901-24-000085
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001599901-23-000035
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  5. 0001193125-22-176510
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Atrium Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/RNA (accessed 2026).
Short form: data: Velarion

The paid brief for Atrium Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Atrium Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Atrium Therapeutics discloses

The companies named in RNA's own disclosed peer group.

Arcturus Therapeutics HoldingsBeam TherapeuticsCrinetics PharmaceuticalsDyne TherapeuticsErascaIGM BiosciencesInhibrx IncJanux TherapeuticsKymera TherapeuticsPliant TherapeuticsRAPT TherapeuticsRocket PharmaceuticalsStoke TherapeuticsVaxcyteVentyx BiosciencesVerve TherapeuticsZentalis Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy